FIREHAWK, safety and effectiveness approved by early clinical studies

SAN FRANCISCO, CALIF.—Early studies provide evidence that the FIREHAWK bioabsorbable polymer sirolimus-eluting stent is safe and effective in CAD patients.

Run-Lin Gao, MD, of Fu Wai Hospital and National Center for Cardiovascular Diseases of China, presented an update of the 4- and 13-month results from the FIREHAWK First-in-Man Study, which assessed the preliminary safety and feasibility of the new-generation DES system (MicroPort). The prospective, single-center pilot study included adult patients with de novo, single lesions in native coronary arteries.

FIREHAWK is a targeted-release abluminal groove filled bioabsorbable polymer SES developed by MicroPort. In the study, the device success rate was 95.7% and lesion and clinical success rates were both 100%. Overall, there was zero incidence of MACE — the primary endpoint of the study — during the 13-month follow-up period.

MicroPort Announced Acquisition of Suzhou BEST Orthopedics Corporation

Reference is made to the announcement of the Company dated 9 September 2011 in relation to the proposed transaction involving the acquisition of 100% equity interest in Suzhou Best. The Board is pleased to announce that the Acquisition was completed on 29 November 2011. Upon the Completion, Suzhou Best has become an indirectly wholly-owned subsidiary of the Company as the Company indirectly holds 100% of the entire issued share capital of Suzhou Best. As a result, financial results of Suzhou Best will be consolidated into the financial statements of the Group.

Suzhou BEST Orthopedics Corporation is one of China’s important domestic manufacturers and marketers of orthopedic implants and related medical instruments, which covers trauma and spine products.

Firebird2 Gained Marketing Approval in Peru

MicroPort is proud to announce that the Firebird2 Rapamycin-eluting Coronary CoCr Stent has gained marketing approval in Peru from August 23, 2011. MicroPort first generation DES Firebird was launched in the local market in 2007.

Aether Distal Protective Device Successfully Registered in Brazil

MicroPort is pleased to announce that our MicroPort Aether Distal Protective Device has been registered successfully in Brazil. It’s the second South American country after Argentina, in which the sale of the product has been approved by the relevant authorities.

The Aether Distal Protective Device System is intended for general use as a guide wire and embolization Protective system during angioplasty, stent and other interventional procedures. It is recommended to use in carotid arteries, coronary and renal arteries and other peripheral vascular system.

Six MicroPort Medical Products Successfully Registered in Venezuela

The first registration for MicroPort Hercules Bifurcated Stent-Graft System and Firebird2 Rapamycin-Eluting Coronary CoCr Stent System achieved approval by Venezuela on November 11th 2011. The products are ready to be launched, and the registration of four other products; JIVE PTCA Balloon Catheter, Firebird Rapamycin-Eluting Coronary Stent System, Hercules Thoracic Stent Graft, and Cronus Stent Graft in Surgical Operation were also approved successfully.

CEC 2011 (China Endovascular Course) Successfully Held in Beijing

The CEC 2011 (China Endovascular Course) jointly sponsored by Chinese PLA (People’s Liberation Army) General Hospital, Shanghai Zhongshan Hospital and Beijing Anzhen Hospital was held in China National Convention Center (Beijing), from November 3 to 6, 2011. MicroPort displayed its single-branched TAA stent graft Castor in the course, which is praised by the physicians and experts for its improved delivery system and flexibility.

MicroPort Orthopedics Obtained a Class III Medical Device License

MicroPort Orthopedics successfully obtained a Class III Medical Device License issued by the SHFDA on November 13 2011.

Announcement Regarding Share Repurchase

A general mandate to repurchase up to 10% of the aggregate nominal amount of the share capital of the Company then in issue (the “Repurchase Mandate”) was granted to the board (the “Board”) of directors of the Company (the “Director(s)”) at the annual general meeting of the Company held on 25 May 2011. In the past 3 months, the Company repurchased 25,000,000 of its own shares pursuant to the Repurchase Mandate.

At the board meeting held on 28 November 2011, the Board authorized the repurchase of the ordinary shares of the Company in on-market from time to time from the date of the board meeting of the Company pursuant to the Repurchase Mandate.